Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability	peptide	Recurrence

Cancer&Entry Information

Cancer Name	endometrial cancer
ICD-0-3	NA
Methods	RNA-seq, Microarray, qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc.
Sample	EC tissues, human EC cell lines(Ishikawa and HEC-1-B)
Expression Pattern	down-regulated
Function Description	by using RNA-seq we report the identification of a new X chromosome-linked lncRNA (lnc-XLEC1) that is aberrantly downregulated during the development of endometrial carcinoma (EC). The overexpression of lnc-XLEC1 reduces the migration and proliferation of EC cells. Flow cytometry analysis indicated that lnc-XLEC1 overexpression resulted in a substantial accumulation of EC cells in the G1 phase. In addition, lnc-XLEC1 had inhibitive effects that may result from its collaboration with MBP-1 during the suppression of the c-Myc expression and the negative regulating of the Cdk/Rb/E2F pathway. The anti-tumor effects of lnc-XLEC1 on EC progression suggest that lnc-XLEC1 has some potential value in anti-carcinoma therapies and deserves further investigation. Our study reported for the first time that the lnc-XLEC1 might be related to the incidence and prognosis of EC. Moreover, we discovered that this process might be related to somatic X dosage compensation and skewed X chromosome inactivation (SXCI).Although lncRNAs lacklacked any detectable open reading frame (ORF), they still might encode the conserved peptides. To examine the coding potential ofThe results showed the low coding potential of lnclnc-XLEC1
Pubmed ID	30698832
Year	2019
Title	X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.

External Links